Related Experiment Video
Updated: Jun 19, 2025
10:48
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
Published on: December 28, 2017
9.5K
Targeted Radionuclide Therapy in Glioblastoma
Xiaobin Zhao1,2,3,4,5, Vivianne Jakobsson1,2,3,5, Yucen Tao1,3,5
1Department of Diagnostic Radiology, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore 119074, Singapore.
ACS Applied Materials & Interfaces
|July 23, 2024
Summary
Targeted radionuclide therapy shows promise for glioblastoma (GBM) treatment. This review explores radionuclides, targeting vectors, and delivery methods to improve outcomes for this aggressive brain cancer.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiochemistry
Background:
- Glioblastoma (GBM) has a poor prognosis despite novel therapies.
- Targeted radionuclide therapy has gained FDA and EMA approval for other cancers.
- This suggests potential for GBM treatment.
Purpose of the Study:
- To review the current status of targeted radionuclide therapy for GBM.
- To highlight therapeutic radionuclides, targeting vectors, and delivery methods.
- To address challenges and propose solutions for GBM radionuclide therapy.
Main Methods:
- Review of therapeutic radionuclides (alpha, beta, Auger electrons).
- Exploration of targeting vectors (small molecules, peptides, antibodies).
- Analysis of locoregional delivery methods (convection-enhanced delivery, local implantation, stereotactic injections).
Main Results:
- Radionuclides can induce potent molecular and cellular damage in GBM.
- Targeting vectors offer selective tumor cell binding.
- Locoregional delivery bypasses the blood-brain barrier effectively.
Conclusions:
- Targeted radionuclide therapy is a promising approach for GBM.
- Further research is needed to overcome existing challenges.
- Optimized strategies can improve patient survival and outcomes.
